dc.description.abstract | Salmonella species cause substantial morbidity, mortality, and disease burden globally
with multiple clinical syndromes. A protective host defense to Salmonella infection
requires both T-cell (cell-mediated) and B-cell (humoral) immune response. Current
vesicle vaccine platforms include inactivated, non-replicating, or synthetic liposomes
which do not produce a robust immune response because they lack foreign distinctness
and complexity. Membrane vesicles (MVs), released in a conserved process by Gramnegative
bacteria, are discrete, spherical nano-particles that are composed of outer
membrane and periplasmic constituents including lipopolysaccharides and proteins.
MVs are promising vaccine candidates for the following reasons: their intrinsic adjuvant
properties, genetically malleability via the parental bacterial strain that can alter vaccine
efficacy, a minimal production cost, and they are stable in powder form. As biologically
derived but nonreplicating particles they are important in the vaccine strategy for
immunocompromised populations. My findings reveal MVs posses important inflammatory properties that demonstrate a viable vaccine platform potential for
Salmonella infection. | en |